Actoxumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Clostridium difficile toxin A
Clinical data
ATC code	none
Identifiers
CAS Number	1245634-25-6
ChemSpider	none
UNII	G3LU5LC5SX
KEGG	D10360
Chemical and physical data
Formula	C₆₄₇₆H₁₀₀₀₀N₁₇₄₀O₂₀₁₀S₄₅
Molar mass	145836.11 g·mol⁻¹

Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.^[1]

This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.^[2] The project was then licensed to Merck & Co., Inc. for further development and commercialization.^[3]

A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.^[4]

References

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§